Literature DB >> 29440241

'If there were water we should stop and drink': neurofibromatosis presenting with diabetes insipidus.

Rachel Barry1, Antoinette O' Connor1, Mohn Hazriq Awang2, Orna O' Toole1.   

Abstract

A 58-year-old right-handed woman presented to our institution with a 1-month history of polydipsia and polyuria. She had a remote history of neurofibroma excision by dermatology and, on examination, was noted to meet the clinical diagnostic criteria for neurofibromatosis type 1. Laboratory investigations revealed hypernatraemia and elevated serum osmolality, accompanied by reduced urinary osmolality. A subsequent water deprivation test confirmed central diabetes insipidus, which responded to treatment with desmopressin. MRI of the brain showed pituitary enlargement, which raised the possibility of an underlying pituitary adenoma or, alternatively, lymphocytic hypophysitis. Both conditions have rarely been described in neurofibromatosis. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  diabetes; neuro genetics; neuroendocrinology; pituitary disorders

Mesh:

Substances:

Year:  2018        PMID: 29440241      PMCID: PMC5836632          DOI: 10.1136/bcr-2017-222741

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Diabetes insipidus in a child with a monosomy-7 associated myelodysplastic syndrome and neurofibromatosis I.

Authors:  Wouter J W Kollen; Lynne M Ball; Petra Snijder; Shama L van Zelderen-Bhola; R Maarten Egeler
Journal:  Med Pediatr Oncol       Date:  2003-04

2.  [RECKLINGHAUSEN'S NEUROFIBROMATOSIS, DIABETES INSIPIDUS AND XANTHOMATOSIS].

Authors:  H GEOFFROY; A ZNIBER; C KOUHEN; R ABITBOL
Journal:  Maroc Med       Date:  1963-08

3.  Neurofibromatosis 1/Noonan syndrome associated with Hashimoto's thyroiditis and vitiligo.

Authors:  Başak Yalcin; Başak Yalcçin; Emine Tamer; Güneş Gür; Pinar Oztas; Muhterem Ustün Polat; Nuran Alli
Journal:  Acta Derm Venereol       Date:  2006       Impact factor: 4.437

Review 4.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

Authors:  D H Gutmann; A Aylsworth; J C Carey; B Korf; J Marks; R E Pyeritz; A Rubenstein; D Viskochil
Journal:  JAMA       Date:  1997-07-02       Impact factor: 56.272

Review 5.  Cranial diabetes insipidus with pituitary stalk lesions.

Authors:  S Wijetilleka; M Khan; A Mon; D Sharma; F Joseph; A Sinha; K Das; J Vora
Journal:  QJM       Date:  2016-04-29

Review 6.  Novel Genetic Causes of Pituitary Adenomas.

Authors:  Francisca Caimari; Márta Korbonits
Journal:  Clin Cancer Res       Date:  2016-10-15       Impact factor: 12.531

7.  [Graves' disease and hyperprolactinemia in a patient with Noonan syndrome neurofibromatosis type 1].

Authors:  P Bolko; R Wasko; J Waligórska; J Narozna; J Sowióski
Journal:  Ann Endocrinol (Paris)       Date:  2004-04       Impact factor: 2.478

8.  A radiologic score to distinguish autoimmune hypophysitis from nonsecreting pituitary adenoma preoperatively.

Authors:  A Gutenberg; J Larsen; I Lupi; V Rohde; P Caturegli
Journal:  AJNR Am J Neuroradiol       Date:  2009-07-23       Impact factor: 3.825

Review 9.  Neurofibromatosis type 1: a multidisciplinary approach to care.

Authors:  Angela C Hirbe; David H Gutmann
Journal:  Lancet Neurol       Date:  2014-08       Impact factor: 44.182

10.  Central diabetes insipidus: an unusual complication in a child with juvenile myelomonocytic leukemia and monosomy 7.

Authors:  Pacharapan Surapolchai; Shau-Yin Ha; Godfrey Chi-Fung Chan; Johannes B Lukito; Thomas S K Wan; Chi-Chiu So; Alan Kwok-Shing Chiang
Journal:  J Pediatr Hematol Oncol       Date:  2013-03       Impact factor: 1.289

  10 in total
  1 in total

1.  Causes and Follow-Up of Central Diabetes Insipidus in Children.

Authors:  Wendong Liu; Jing Hou; Xiuqin Liu; Limin Wang; Guimei Li
Journal:  Int J Endocrinol       Date:  2019-03-27       Impact factor: 3.257

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.